FMP
SeaStar Medical Holding Corporation
ICU
NASDAQ
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
1.25 USD
0 (0%)
ICU Financial Statements
Year
2024
2023
2022
2021
Total Revenue
135k
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
135k
0
0
0
Operating Expenses
17.98M
14.21M
11.61M
4.45M
Research and Development
9.11M
5.97M
2.82M
2.77M
Selling, General & Administrative Expenses
8.87M
8.04M
6.6M
1.68M
Selling & Marketing Expenses
0
32k
0
0
General & Administrative Expenses
8.87M
8.01M
6.6M
1.68M
Other Expenses
0
200k
0
91k
Operating Income
-17.84M
-14.21M
-11.61M
-4.45M
Total Other Income/Expenses Net
-6.99M
-12.02M
-11.4M
-148k
Income Before Tax
-24.83M
-26.23M
-23.01M
-4.6M
Income Tax
3k
0
1k
-1k
Net Income
-24.83M
-26.23M
-23.01M
-4.6M
Basic EPS
-5.05
-30.29
-70.16
-15.9
EPS Diluted
-5.05
-30.26
-70.07
-15.87
Basic Average Shares
4.92M
866k
328k
289k
Diluted Average Shares
4.92M
866.81k
328.45k
289.55k
EBITDA
-24.58M
-11.14M
-11.61M
0
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-114.73M
-99.33M
-76.31M
-71.72M
Net Income
-24.83M
-26.23M
-23.01M
-4.6M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-139.56M
-114.73M
-99.33M
-76.31M
Other Distributions
-24.83M
-15.41M
-23.01M
-4.6M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
0
0
0
0
Annual Depreciation
0
14.01M
11.61M
4.45M
Capital Expenditure
0
0
0
0
Net PPE
0
-14.01M
-11.61M
-4.45M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
